Clinical Trials Logo

Healthy Controls clinical trials

View clinical trials related to Healthy Controls.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03206463 Terminated - Bipolar Disorder Clinical Trials

Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder

THC-BD
Start date: August 1, 2017
Phase: Phase 1
Study type: Interventional

The overarching goal of this study is to characterize the acute cognitive and psychophysiological effects of the main psychoactive constituent of cannabis, 9-delta-tetrahydrocannabinol (THC) in individuals with euthymic bipolar disorder (BD), and to begin probing the mechanisms that may underlie its effects in this illness. This study is expected to contribute to a better characterization of specific effects of THC in individuals with BD compared to healthy controls (HC).

NCT ID: NCT00838851 Terminated - Healthy Controls Clinical Trials

Response of Airway Cells to 20,000 EU of Endotoxin in Normal Adults

Start date: August 2003
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the range of neutrophil response (influx of PMNs to the airways as determined in sputum) after inhalation of CCRE (20,000 EU).

NCT ID: NCT00612872 Terminated - Multiple Sclerosis Clinical Trials

Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects

CLINDE
Start date: January 2008
Phase: Phase 1
Study type: Interventional

To assess the dynamic uptake and washout of 123-I CLINDE, a potential imaging biomarker for inflammatory changes in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and subjects with Alzheimer (AD) or Parkinson disease (PD). To perform blood metabolite characterization of 123-I CLINDE in healthy and subjects with AD or PD to determine the nature of metabolites in assessment of 123-I CLINDE as a single photon computed tomography (SPECT) brain imaging agent. Evaluate the test/retest reproducibility of 123-I CLINDE, and SPECT in AD and PD subjects and healthy controls